

Other Formats: [Citation](#) [MEDLINE](#)Links: [Related Articles](#)☐ Order this document*J Clin Oncol* 1999 Feb;17(2):585-92

## Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer.

Hidalgo M, Castellano D, Paz-Ares L, Gravalos C, Diaz-Puente M, Hitt R, Alonso S, Cortes-Funes H

Division of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain.  
manuel\_hidalgo@msmtp.idde.saci.org

**PURPOSE:** To determine the maximum-tolerated dose (MTD), dose-limiting toxicities, and efficacy of gemcitabine combined with fluorouracil (5-FU) in patients with pancreatic cancer. **PATIENTS AND METHODS:** Patients with measurable, locally advanced, nonresectable or metastatic pancreatic cancer were candidates for the study. 5-FU was given via protracted venous infusion (PVI) at a fixed dosage of 200 mg/m<sup>2</sup>/d, and gemcitabine was administered weekly for 3 consecutive weeks every 4 weeks. The initial dose of gemcitabine was 700 mg/m<sup>2</sup> and was escalated in increments of 100 mg/m<sup>2</sup>/wk until the appearance of severe toxicity. Measurements of efficacy included the following: response rate; clinical benefit response, which is a composite measurement of pain, performance status, and weight loss; time to disease progression; and survival. **RESULTS:** Twenty-six patients received a total of 109 courses. Dose-limiting toxicity, which consisted of grade 4 neutropenia with fever (one patient) and grade 4 thrombocytopenia (one patient), was observed in two of three patients treated with 1,100 mg/m<sup>2</sup>/wk of gemcitabine. On the basis of these results, the MTD of gemcitabine with 5-FU via PVI on this schedule was 1,000 mg/m<sup>2</sup>. Sixteen patients developed grade 3-4 neutropenia, and three patients developed grade 3-4 thrombocytopenia. Grade 3-4 nonhematologic toxicity consisted of diarrhea (two patients) and cutaneous toxicity, asthenia, edema, mucositis, and nausea and vomiting (one patient each). The delivered dose-intensity of gemcitabine was similar at the 1,000 mg/m<sup>2</sup> dose level (599 mg/m<sup>2</sup>/wk) as at the 900 mg/m<sup>2</sup> (601 mg/m<sup>2</sup>/wk) dose level. For this reason, the recommended dose of gemcitabine for phase II evaluation on this schedule was 900 mg/m<sup>2</sup>. Five patients had objective responses (one complete response and four partial responses; response rate, 19.2%; 95% confidence interval [CI], 6.5 to 39.3), and 10 patients had improvement of disease-related symptoms (45%; 95% CI, 24 to 67). After a median follow-up of 17.7 months (range, 7.8 to 24.8 months), the median progression-free survival and overall survival times were 7.4 months (95% CI, 3.3 to 11.4) and 10.3 months (95% CI, 8.1 to 12.5), respectively. **CONCLUSION:** The MTD of gemcitabine when combined with 5-FU via PVI on this schedule was 1,000 mg/m<sup>2</sup>/wk; however, on the basis of administered dose-intensity, the recommended dose for additional investigation is 900 mg/m<sup>2</sup>. This combination chemotherapy regimen was well tolerated and showed promising antitumor activity in the treatment of pancreatic cancer.